Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques

Inhibition of cholesteryl ester transfer protein (CETP) has been vigorously pursued as a potential therapy to treat patients who are at an elevated risk for coronary artery disease. Anacetrapib, a novel CETP inhibitor, has been shown clinically to raise HDL cholesterol and reduce LDL cholesterol whe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2014-10, Vol.740, p.410-416
Hauptverfasser:	Roddy, Thomas P., McLaren, David G., Chen, Ying, Xie, Dan, Dunn, Keiana, Kulick, Alison, Szeto, Daphne, Forrest, Gail, Albanese, Kelly, Donnelly, Marcie, Gai, Cesaire, Gewain, Andrew, Lederman, Harmony, Jensen, Kristian K., Ai, Xi, Vachal, Petr, Akinsanya, Karen O., Cleary, Michele A., Previs, Stephen F., Dansky, Hayes M., Johns, Douglas G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anacetrapib Animals Anticholesteremic Agents - pharmacology Apolipoproteins - blood Cholesterol Ester Transfer Proteins - antagonists & inhibitors Cholesterol Ester Transfer Proteins - blood Cholesterol, HDL - blood Cholesterol, LDL - blood Cholesteryl ester transfer protein Lipoproteins Macaca mulatta Male Oxazolidinones - pharmacology PCSK9 Proprotein Convertases - blood Rhesus macaques Serine Endopeptidases - blood Triglycerides - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!